Abhijit Dandapat

Person

San Diego, CA, US

People

Patents Grantslast 30 patents

Information Patent Grant
Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce m...
- Patent number 11,813,292
- Issue date Nov 14, 2023
- Immunity Bio, Inc.
- Patrick Soon-Shiong
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Fc-epsilon car
- Patent number 11,643,452
- Issue date May 9, 2023
- ImmunityBio, Inc.
- Laurent H. Boissel
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Grant
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antige...
- Patent number 11,077,143
- Issue date Aug 3, 2021
- NantKwest Inc.
- Hans G. Klingemann
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
USE OF CD33CAR MODIFIED HIGH AFFINITY NK CELLS (T-HANK) TO REDUCE M...
- Publication number 20240016849
- Publication date Jan 18, 2024
- ImmunityBio, Inc.
- Patrick Soon-Shiong
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
FC-EPSILON CAR
- Publication number 20230272042
- Publication date Aug 31, 2023
- ImmunityBio, Inc.
- Laurent H. Boissel
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Elimination of BCMA-positive malignancies by CAR expressing NK cells
- Publication number 20230172982
- Publication date Jun 8, 2023
- ImmunityBio, Inc.
- Laurent H. Boissel
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
IL-2 DEPENDENT NK-92 CELLS WITH STABLE FC RECEPTOR EXPRESSION
- Publication number 20220017594
- Publication date Jan 20, 2022
- NantKwest, Inc.
- Francisco Navarro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
FC-EPSILON CAR
- Publication number 20210347850
- Publication date Nov 11, 2021
- ImmunityBio, Inc.
- Laurent H. Boissel
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGE...
- Publication number 20210322477
- Publication date Oct 21, 2021
- ImmunityBio, Inc.
- Hans G. Klingemann
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGE...
- Publication number 20210315934
- Publication date Oct 14, 2021
- ImmunityBio, Inc.
- Hans G. Klingemann
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
FC-EPSILON CAR (Very imp commercially - in clinical trial)
- Publication number 20210198342
- Publication date Jul 1, 2021
- NantKwest, Inc.
- Laurent H. Boissel
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC vali...
- Publication number 20210040175
- Publication date Feb 11, 2021
- NantKwest, Inc.
- Hans G. Klingemann
- G01 - MEASURING TESTING
Information Patent Application
USE OF CD33CAR MODIFIED HIGH AFFINITY NK CELLS (T-HANK) TO REDUCE M...
- Publication number 20210038645
- Publication date Feb 11, 2021
- NantKwest, Inc.
- Patrick Soon-Shiong
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGE...
- Publication number 20200129552
- Publication date Apr 30, 2020
- NantKwest, Inc.
- Hans G. Klingemann
- C07 - ORGANIC CHEMISTRY

Abhijit Dandapat

Person

Patents Grantslast 30 patents

Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce m...

Fc-epsilon car

Elimination of PD-L1-positive malignancies by PD-L1 chimeric antige...

Patents Applicationslast 30 patents

USE OF CD33CAR MODIFIED HIGH AFFINITY NK CELLS (T-HANK) TO REDUCE M...

FC-EPSILON CAR

Elimination of BCMA-positive malignancies by CAR expressing NK cells

IL-2 DEPENDENT NK-92 CELLS WITH STABLE FC RECEPTOR EXPRESSION

FC-EPSILON CAR

ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGE...

ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGE...

FC-EPSILON CAR (Very imp commercially - in clinical trial)

Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC vali...

USE OF CD33CAR MODIFIED HIGH AFFINITY NK CELLS (T-HANK) TO REDUCE M...

ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGE...